Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief: Amylin Pharmaceuticals

Executive Summary

Amylin Pharmaceuticals: Files registration with the Securities & Exchange Commission for secondary public offering of approximately 3.8 mil. shares of common stock, San Diego-based Amylin announces Sept. 1. The company will offer 2.5 mil. shares to the public and has reserved approximately 1.3 mil. shares worth about $10 mil. for sale directly to Johnson & Johnson Development Corp. J&J is Amylin's corporate partner for the development of pramlintide (an analog of amylin), which is in Phase III trials for Type I (juvenile onset) diabetes and in Type II (adult onset) insulin-dependent patients. Proceeds from the offering will be used to fund the Phase III pivotal trials, among other uses. Hambrecht & Quist, Vector Securities and UBS Securities are underwriting the offering. Amylin will have roughly 28 mil. shares of common stock outstanding after the offering, including the J&J shares but excluding any sales to the underwriters to cover over-allotments...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel